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Mast cells (MCs) are key effector cells in allergic reac-
tions. However, the inhibitory mechanism that pre-
vents excessive activation of MCs remains elusive.
Here we show that leukocyte mono-immunoglob-
ulin-like receptor 3 (LMIR3; also called CD300f) is a
negative regulator of MC activation in vivo. LMIR3
deficiency exacerbated MC-dependent allergic re-
sponses inmice, includinganaphylaxis, airway inflam-
mation, and dermatitis. Both physical binding and
functional reporter assays via an extracellular domain
of LMIR3 showed that several extracellular lipids
(including ceramide) and lipoproteins were possible
ligands for LMIR3. Importantly, MCs were fre-
quently surrounded by extracellular ceramide in vivo.
Upon engagement of high-affinity immunoglobulin
E receptor, extracellular ceramide-LMIR3 binding in-
hibited MC activation via immunoreceptor tyrosine-
based inhibitory and switch motifs of LMIR3.
Moreover, pretreatment with LMIR3-Fc fusion protein
or antibody against either ceramide or LMIR3 inter-
fered with this binding in vivo, thereby exacerbating
passive cutaneous anaphylaxis. Thus, the interaction
between extracellular ceramide and LMIR3 sup-
pressed MC-dependent allergic responses.
INTRODUCTION
Mast cells are key effector cells in immunoglobulin E (IgE)-
associated immune responses, including anaphylaxis and
allergic disorders. The high-affinity IgE receptor (FcεRI) is ex-
pressed in mast cells as a heterotetrameric complex composed
of an IgE-binding a chain, a b chain, and two disulfide-linked g
chains. Engagement of IgE-bound FcεRI by multivalent antigens
triggers mast cell activation, leading to its degranulation and
secretion of preformed chemical mediators such as vasoactive
amines. In addition, activated mast cells secrete de novo syn-Ithesized lipid mediators, cytokines, and chemokines. An initial
step in FcεRI signaling is an activation of b chain-associated
Lyn, which phosphorylates immunoreceptor tyrosine-based
activation motif (ITAM) in the cytoplasmic domains of b and g
chains of FcεRI. Subsequent activation of the kinases Syk and
Fyn and the phosphatidylinositol-3-OH kinase are essential for
mast cell activation (Blank et al., 1989; Kawakami and Galli,
2002; Parravicini et al., 2002; Kraft and Kinet, 2007; Kalesnikoff
and Galli, 2008). Such activation is counterbalanced by immu-
noreceptor tyrosine-based inhibitory motif (ITIM)-containing
receptors (Ravetch and Lanier, 2000): FcgRIIb (Dae¨ron et al.,
1995; Ono et al., 1996; Ujike et al., 1999), gp49B1 (Daheshia
et al., 2001), PIR-B (Kubagawa et al., 1997; Masuda et al.,
2007), and Allergin-1 (Hitomi et al., 2010).
The leukocytemono-immunoglobulin-like receptor (LMIR; also
called CD300, CLM, or MAIR) (Chung et al., 2003; Kumagai et al.,
2003; Yotsumoto et al., 2003) family belongs to the paired
immune receptors. An inhibitory receptor LMIR3 (also called
CD300f, CLM-1, or MAIR-V) is highly expressed in mast cells
(Izawa et al., 2007). Coengagement of FcεRI and LMIR3 inhibits
FcεRI-mediated activation of mouse bone-marrow-derived
mast cells (BMMCs) (Izawa et al., 2009). LMIR3 delivers an inhib-
itory signal via its two ITIMs and a single immunoreceptor
tyrosine-based switchmotif (ITSM) that can recruit Src homology
2 domain-containing protein phosphatase-1 (SHP-1) and/or
SHP-2 (Izawa et al., 2009). Although LMIR3 had been shown to
negatively regulate autoimmune demyelination in the central
nervous system (Xi et al., 2010), whether LMIR3 regulates mast
cell activation in vivo remained unknown. Here, we found that
whereas LMIR3 deficiency failed to influence FcεRI-mediated
activation of BMMCs, it profoundly enhanced mast cell-depen-
dent allergic responses in mice. These results suggest that mast
cell activation in vivo is suppressed by the interaction between
LMIR3 and its unknown ligand surrounded by tissue mast cells.
To identify a ligand for LMIR3, we generated an Fc fusion
protein containing an extracellular domain of LMIR3 (LMIR3-
Fc). In addition, we used reporter cell lines to show that the
binding of an unknown ligand to an extracellular domain of
LMIR3 could induce green fluorescent protein (GFP) expression
driven by transcription factor NFAT. We have previously identi-
fied T cell immunoglobulin mucin 1 (TIM1) as a ligand for anmmunity 37, 827–839, November 16, 2012 ª2012 Elsevier Inc. 827
A D
B
C
E
Figure 1. Normal Development of LMIR3-
Deficient Mast Cells
(A) Mast cell numbers in ear skin, back skin, and
stomach of WT or LMIR3-deficient (Cd300lf/)
(KO) mice (n = 7 per genotype).
(B) Surface expression levels of FcεRI and c-kit
(left) or LMIR3 (right) in WT or Cd300lf/ BMMCs.
(C and D) Release of b-hexosaminidase (C) or
production of IL-6 (top) or TNF-a (bottom) (D) from
anti-TNP IgE-sensitizedWT orCd300lf/BMMCs
stimulated with indicated concentrations of TNP-
BSA for 8 hr (C) or 1 hr (D).
(E) Production of IL-6 from Cd300lf/ BMMCs
transduced with LMIR3WT, LMIR3(Y241F-Y289F-
Y325F) mutant, or mock that were subjected to
coengagement of IgE-bound FcεRI and the
transduced LMIR3 for 8 hr.
Data are representative of four independent
experiments (mean and SD in C–E). *p < 0.01
(Student’s t test). See also Figure S1.
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Ceramide Is a Ligand for LMIR3 in Mast Cellsactivating receptor LMIR5 (also called CLM-7) by retrovirus-
mediated expression cloning (Yamanishi et al., 2010). However,
LMIR3-Fc failed to bind a variety of cells examined. Therefore,
we hypothesized that a ligand for LMIR3 might belong to extra-
cellular proteins or lipids. Interestingly, LMIR3-Fc bound to
several lipids, including ceramide, and lipoproteins. Moreover,
the binding of these lipids and lipoproteins to an extracellular
domain of LMIR3 induced GFP expression in the reporter cell
lines. Although it has been recently reported that LMIR3 recog-
nizes phosphatidylserine (PS) and promotes phagocytosis of
apoptotic cells (Choi et al., 2011), our results did not provide
any evidence that PS worked as a functional ligand for LMIR3.
Importantly, FcεRI-mediated activation of wild-type (WT)
BMMCs, but not of LMIR3-deficient (Cd300lf/) BMMCs, was
inhibited by plate-coated or liposomal ceramide.
Ceramide is a sphingolipid generated mainly by hydrolysis of
sphingomyelin or by de novo synthesis via ceramide synthase.
Ceramide regulates a variety of cellular processes, including
differentiation, inflammation, proliferation, and apoptosis, in a
cell type-dependent manner (Kolesnick, 2002; Meyer zu Hering-
dorf et al., 2002; Zheng et al., 2006). Recent studies have demon-
strated that ceramide is abundant in the epidermis and func-
tions as the epidermal permeability barrier: ceramide content is828 Immunity 37, 827–839, November 16, 2012 ª2012 Elsevier Inc.decreased in the skin of atopic dermatitis
(AD) (Meyer zu Heringdorf et al., 2002; Ka-
wakami et al., 2009). Although intracellular
and extracellular ceramide have wide-
ranging functions, our results illustrate
a role for the extracellular lipid ceramide
as an antiallergic tissue component that
binds to LMIR3, thereby inhibiting mast
cell-dependent allergic responses.
RESULTS
Normal Development of LMIR3-
Deficient Mast Cells
To delineate the in vivo function of
LMIR3, we generated LMIR3-deficient(Cd300lf/) mice (Figures S1A–S1C available online). Consis-
tent with a previous report (Xi et al., 2010), Cd300lf/ mice ex-
hibited no significant differences from WT mice in myeloid and
lymphoid development (Figures S1D–S1H). LMIR3 deficiency
did not affect mast cell numbers in ear skin, back skin, or
stomach in mice (Figure 1A). WT and Cd300lf/ BMMCs dis-
played equivalent expression levels of c-kit and FcεRI (Figures
1B and S1I) and exhibited comparable growth and apoptosis
(Figures S1J and S1K). Surface expression of other LMIR was
comparable between WT and Cd300lf/ BMMCs (Figure S1L).
Thus, LMIR3 deficiency did not influence mast cell development
in vitro or in vivo. When IgE-sensitized BMMCs were stimulated
with specific antigens, LMIR3 deficiency did not alter degranula-
tion or cytokine production (Figures 1C and 1D) nor the tyrosine
phosphorylation of cellular proteins (Figure S1M). Coengage-
ment of FcεRI and LMIR3 impaired cytokine production in WT
BMMCs (Izawa et al., 2009), which was not observed in
Cd300lf/ BMMCs (Figure S1N). We transduced Cd300lf/
BMMCs with LMIR3 WT, LMIR3(Y241F-Y289F-Y325F) mutant,
or mock, that exhibited equivalent expression levels of both
FcεRI and c-kit as well as those of the transduced LMIR3 (Fig-
ure S1O). We confirmed that coengagement of FcεRI and
LMIR3(Y241F-Y289F-Y325F) mutant failed to impair cytokine
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Figure 2. Enhanced Passive Systemic and
Cutaneous Anaphylaxis in LMIR3-Deficient
Mice
(A–C) PSA reactions.
(A and C) Rectal temperature changes were
monitored in (A) WT and LMIR3-deficient
(Cd300lf/) mice (n = 6 per genotype) or (C) WT or
Cd300lf/ mice at 2 months after transplantation
with WT or Cd300lf/ BM (n = 4 per group).
(B) Serum levels of histamine in WT and
Cd300lf/ mice at 3 min before (n = 3 per group)
and after (n = 6 per group) antigen challenge.
(D–F) Mice were injected intravenously with
(D and F) Evans blue dye containing DNP-HSA
after IgE sensitization or (E) Evans blue dye con-
taining histamine. Quantification of Evans blue dye
that extravasated into ears at (D, F) 30 min or (E)
3 min after injection.
(D) WT and Cd300lf/mice (n = 11 per genotype).
(E) WT (n = 6) and Cd300lf/ (n = 7) mice.
(F) WT or Cd300lf/ mice at 2 months after
transplantion with WT or Cd300lf/ BM (n = 6 per
group).
(G and H) Mice were applied with dinitro-
fluorobenzene on ears after IgE sensitization.
(G) Ear thickness was measured in WT or
Cd300lf/ mice (n = 6 per genotype).
(H) Sections of antigen-challenged ears were
stained with hematoxylin and eosin. Scale bars
represent 100 mm.
Data are representative of three independent
experiments (mean and SD in A–G). *p < 0.01
(Student’s t test). See also Figure S2.
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Ceramide Is a Ligand for LMIR3 in Mast Cellsproduction in the transduced Cd300lf/ BMMCs stimulated by
FcεRI crosslinking alone (Figure 1E; Izawa et al., 2009). Thus,
only when LMIR3 and FcεRI were coengaged in WT BMMC did
LMIR3 deliver an inhibitory signal via its ITIMs and ITSM in vitro.
Enhanced Responses of FcεRI-Mediated Passive
Anaphylaxis in Cd300lf–/– Mice
We first elicited FcεRI-mediated passive systemic anaphylaxis
(PSA) reactions (Masuda et al., 2007). WT or Cd300lf/ mice
were challenged with dinitrophenyl-conjugated human serum
albumin (DNP-HSA) 24 hr after intravenous injection of anti-
DNP IgE. Remarkably, the magnitude and duration of body
temperature drops were enhanced in Cd300lf/ mice com-
pared to WT mice (Figure 2A), in accordance with the higher
amounts of plasma histamine in Cd300lf/ mice at 3 min after
antigen challenge (Figure 2B). In both WT and Cd300lf/Immunity 37, 827–839, Nmice, PSA was completely suppressed
by pretreatment with cyproheptadine, an
antagonist of histamine and serotonin,
but not with CV6029, an antagonist of
platelet activating factor (PAF) receptor
(Figure S2A). We then used WT or
Cd300lf/ mice receiving whole WT or
Cd300lf/ BM transplants. At 2 months
after BM transplantation, LMIR3 was
expressed in mast cells residing in ear
skin or peritoneal cavity of WT BM-transplanted mice, whereas LMIR3 expression was lacking
in those of Cd300lf/ BM-transplanted mice (Figures S2B
and S2C). In addition, the numbers of skin mast cells were similar
in each group of BM-transplanted mice (Figure S2D). BothWT or
Cd300lf/ mice transplanted with Cd300lf/ BM displayed
a stronger response of PSA than the mice transplanted with
WT BM (Figure 2C).
Next, we elicited FcεRI-mediated passive cutaneous anaphy-
laxis (PCA) reactions (Hata et al., 1998). Mice were challenged by
intravenous injection of DNP-HSA and Evans blue 24 hr after
intradermal injection of anti-DNP IgE in their ears. Notably, dye
extravasation in IgE-injected sites in Cd300lf/ mice was
greater than in that of WT mice (Figure 2D). Pretreatment with
cyproheptadine dampened these responses in Cd300lf/
mice as well as inWTmice (Figure S2E). On the other hand, intra-
dermal injection of histamine and Evans blue dye in the earsovember 16, 2012 ª2012 Elsevier Inc. 829
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Figure 3. Enhanced PCA Responses in
LMIR3-Deficient Mice Were due to the
Lack of LMIR3-Mediated Inhibitory Signals
in Mast Cells
Mice were injected intravenously with Evans blue
dye containing DNP-HSA after IgE sensitization.
Quantification of Evans blue dye that had ex-
travasated into ears. Data are representative of
three independent experiments (mean and SD).
*p < 0.05 (Student’s t test).
(A) KitW-sh/W-sh mice (n = 3) or KitW-sh/W-sh mice
injected intradermally with WT BMMCs (n = 5) or
Cd300lf/ BMMCs (n = 5).
(B) KitW-sh/W-sh mice injected intradermally
with Cd300lf/ BMMCs transduced with LMIR3
WT (n = 9), LMIR3(Y241F-Y289F-Y325F) mutant
(n = 7), or mock (n = 8).
(C) WT or Cd300lf/ mice injected intradermally
with 10 mg of either LMIR3 Ab (3-14-11) or isotype
control Ab together with anti-DNP IgE (n = 7 per
group).
(D) WT or Cd300lf/ mice injected intradermally
with 10 mg of either LMIR3-Fc or control Fc
together with anti-DNP IgE (n = 5 per group). See
also Figure S3.
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Ceramide Is a Ligand for LMIR3 in Mast Cellsinduced comparable levels of dye extravasation in WT and
Cd300lf/mice (Figure 2E). Analysis of the mice after BM trans-
plantation showed that PCA responses were enhanced in
Cd300lf/ BM-transplanted mice as compared to WT BM-
transplanted mice (Figure 2F). Moreover, we elicited a different
type of FcεRI-mediated PCA reaction (Hata et al., 1998). Mice
were challenged by epicutaneous application of dinitrofluoro-
benzene on the ears 24 hr after intravenous injection of anti-
DNP IgE. Of note, ear swelling with inflammatory edema was
greater in Cd300lf/ mice than in WT mice during the entire
observation period (Figures 2G and 2H). Early-phase PCA and
PSA reactions largely depend on histamine and serotonin
secreted by mast cells, whereas late-phase PCA reactions are
associated with mast cell-derived cytokines in mice (Hata
et al., 1998). Overall, LMIR3 deficiency exacerbated FcεRI-
mediated anaphylactic responses in mice, presumably because
LMIR3-deficient mast cells secreted more histamine, serotonin,
and cytokines than did WT mast cells in vivo.
LMIR3-Dependent Inhibition of Mast Cell Activation
In Vivo
To obtain direct evidence that enhanced responses of PCA in
Cd300lf/ mice depended on LMIR3 deficiency in mast cells,
we used mast cell-deficient KitW-sh/W-sh mice engrafted intrader-
mally withWT orCd300lf/BMMCs. At 8weeks after transplan-
tation, similar numbers of mast cells were found in ear skin of
BMMC-engrafted KitW-sh/W-sh mice (Figure S3A). KitW-sh/W-sh
mice did not exhibit significant levels of dye extravasation in
response to antigen stimulation (Figure 3A). The amounts of ex-
travasated dye in Cd300lf/ BMMC-transplanted KitW-sh/W-sh
mice were higher than those in WT BMMC-transplanted830 Immunity 37, 827–839, November 16, 2012 ª2012 Elsevier Inc.KitW-sh/W-sh mice (Figure 3A). Moreover,
we induced the same PCA reactions in
KitW-sh/W-sh mice engrafted intradermallywith Cd300lf/ BMMC transfectants. At 8 weeks after trans-
plantation, similar numbers of mast cells were found in ear skin
of each group of the transplanted mice (Figure S3B). The results
showed that KitW-sh/W-sh mice engrafted with LMIR3-deficient
BMMCs exhibited stronger responses than KitW-sh/W-sh mice
engrafted with LMIR3 WT-sufficient BMMCs (Figure 3B). It
should be noted that KitW-sh/W-sh mice transplanted with
LMIR3(Y241F-Y289F-Y325F) mutant-transduced Cd300lf/
BMMCs exhibited the enhanced responses at levels comparable
to those of KitW-sh/W-sh mice transplanted with LMIR3-deficient
BMMCs (Figure 3B). Taken together, these results indicated
that FcεRI-mediated PCA responses were negatively regulated
by LMIR3-dependent inhibitory signals through its ITIMs and
ITSM in mast cells. Interestingly, when pretreated with LMIR3
antibody (Ab), but not with control Ab, WT mice exhibited
enhanced PCA responses at levels comparable to those ex-
hibited by Cd300lf/ mice (Figure 3C). Similarly, pretreatment
with LMIR3-Fc, but not with control Fc, enhanced the PCA
responses in WT mice to a level similar to that observed in
Cd300lf/ mice (Figure 3D). Notably, pretreatment with either
LMIR3 Ab or LMIR3-Fc failed to further enhance PCA responses
in Cd300lf/ mice (Figures 3C and 3D). Collectively, PCA
responses inWTmice seemed to be inhibited by the in vivo inter-
action between LMIR3 and its ligands surrounded by mast cells.
Exacerbation of Mast Cell-Dependent Airway
Inflammation and Dermatitis in Cd300lf–/– Mice
To clarify the role of LMIR3 in the pathogenesis of other allergic
diseases, we used a mast cell-dependent airway inflammation
model. According to the established protocol (Williams and Galli,
2000; Taube et al., 2004; Xiao et al., 2011), mice received an
Immunity
Ceramide Is a Ligand for LMIR3 in Mast Cellsintranasal challenge with ovalbumin (OVA) after the sensitization
to OVA without adjuvant. Although OVA-induced chronic airway
inflammation, characterized by the accumulation of inflamma-
tory granulocytes and goblet cell hyperplasia, was observed in
mast cell-sufficient mice, but not inKitW-sh/W-shmice, it was dras-
tically enhanced in Cd300lf/ mice (Figures 4A and S4A–S4C).
In accordance, OVA-challenged lung weight was considerably
higher in Cd300lf/ mice than in WT mice (Figure S4D). LMIR3
deficiency increased the inflammatory cells accumulated in
the bronchoalveolar fluids (BALF) of the challenged mice,
caused primarily by increased eosinophils (Figure 4B). In addi-
tion, Cd300lf/ mice exhibited higher amounts of IL-4, IL-5,
and IL-13 in BALF as compared to WT mice (Figure 4C). Then,
KitW-sh/W-sh mice intravenously transplanted with WT or
Cd300lf/ BMMCs were used 5 months after transplantation.
Cd300lf/ BMMC-transplanted KitW-sh/W-sh mice exhibited
enhanced airway inflammation with higher numbers of inflamma-
tory cells and levels of cytokines in BALF, when compared with
WT BMMC-transplanted KitW-sh/W-sh mice (Figures S4A–S4C).
We next used a mouse AD model, in which AD-like lesions in
ear skin were induced by dust mite extract (Kang et al., 2007).
WT mice exhibited weak but significant levels of ear thickness
at 14 to 19 days from the first application, whereas KitW-sh/W-sh
mice did not do so (Figure 4D), implicating mast cells in the path-
ogenesis of AD-like skin lesions in this model. Cd300lf/ mice
displayed enhanced swelling of the ears, where the marked
infiltration of leukocytes was observed in the dermis (Figures
4D and 4E). Moreover, we used this model in KitW-sh/W-sh mice
engrafted intradermally with Cd300lf/ BMMC transfectants.
KitW-sh/W-sh mice engrafted with Cd300lf/ BMMCs transduced
with either LMIR3(Y241F-Y289F-Y325F) mutant or mock dis-
played the greater swelling of ears with AD-like skin lesions
when compared with KitW-sh/W-sh mice engrafted with LMIR3
WT-sufficient BMMCs (Figure 4F). Taken together, these results
indicated that LMIR3 negatively regulated mast cell-dependent
airway inflammation and dermatitis in mice.
Identification of Possible Ligands for LMIR3
As a tool in our ligand search, we used the reporter cell lines
(2B4-GFP) (Ohtsuka et al., 2004; Yamasaki et al., 2008). A
chimera receptor (LMIR3-CD3z), composed of an extracellular
and transmembrane domain of Flag-tagged LMIR3 fused to an
intracellular domain of CD3z, was transduced into 2B4-GFP cells
to generate 2B4-LMIR3-GFP cells (Figure S5A). The addition of
a soluble LMIR3 Ab or Flag Ab to the culture did not induce
GFP expression in 2B4-LMIR3-GFP cells (data not shown).
However, crosslinking of the chimera receptor (LMIR3-CD3z)
by plate-coated LMIR3 Ab strongly induced GFP expression in
2B4-LMIR3-GFP cells but not in 2B4-GFP cells (Figure 5B).
This induction of GFP in 2B4-LMIR3-GFP cells was blocked by
adding a soluble LMIR3 Ab (Figure 5B). We therefore assumed
that GFP expression would be induced in 2B4-LMIR3-GFP cells,
but not in 2B4-GFP cells, on plates coated with any ligand for
LMIR3. GFP expression was not induced in 2B4-LMIR3-GFP
cells on the plates coated with extracellular matrix proteins,
such as fibronectin, fibrinogen, vitronectin, or a soluble form of
basement membrane including laminin, collagen IV, entactin,
and heparin sulfate proteoglycan (Figure S5B). To find a candi-
date ligand for LMIR3 out of the variety of lipids, we performedIa binding assay prior to a reporter assay. When membranes
spotted with many different types of lipids were incubated with
LMIR3-Fc in the presence of Ca2+, immunoblot analysis showed
that LMIR3-Fc strongly bound to ceramide but not to the other
lipids tested (Figure 5A). In contrast, neither TIM1-Fc nor control
Fc bound to ceramide (Figure 5A). As reported (Kobayashi et al.,
2007; Miyanishi et al., 2007), TIM1-Fc bound to phosphatidyl-
serine (PS), whereas LMIR3-Fc did not bind to PS under the
same conditions (Figure 5A). None of the lipids on the mem-
branes were bound by control Fc (Figure 5A). To test whether
ceramide worked as a ligand for LMIR3, 2B4-LMIR3-GFP cells
were incubated on the plates coated with C-24 ceramide.
Intriguingly, considerable amounts of GFP expression and IL-2
production were induced by C-24 ceramide in 2B4-LMIR3-
GFP cells but not in 2B4-GFP cells (Figures 5B and 5C). In addi-
tion, ceramide-induced GFP expression and IL-2 production
were both abolished by the addition of a soluble LMIR3 Ab,
but not by a control Ab, just after the incubation of 2B4-
LMIR3-GFP cells on the ceramide-coated plates (Figures 5B,
5C, and S5C). Other ceramides, C8-ceramide and egg ceram-
ide, also behaved in the same way as C-24 ceramide (Figure 5B),
whereas neither glucosylceramide nor alpha-galactosylcera-
mide (a-GalCer) induced GFP expression in 2B4-LMIR3-GFP
cells (Figure S5D). In addition, GFP expression was not induced
in 2B4-LMIR3-GFP cells on the plates coated with PS, phospha-
tidylethanolamine (PE), sphingomyelin (SM), sphingosin, choles-
terol, lysophosphatidylcholine (lysolecithin), or lipid A (Figure 5D).
Although LMIR3-Fc failed to bind both phosphatidylcholine
(PC) and sphingosylphosphocholine (SPC) spotted on the
membranes (Figure 5A), GFP expression was induced in 2B4-
LMIR3-GFP cells on the plates coated with these lipids, which
was prevented by the addition of a soluble LMIR3 Ab (Figure 5D).
To further test whether LMIR3-Fc was able to directly bind PC or
SPC, we used enzyme-linked immunosorbent assay (ELISA) as
a different binding assay. LMIR3-Fc, as compared to Fc, signif-
icantly bound to PC, SPC, and C-24 ceramide (Figures S5E and
S5F). We found no binding of LMIR3-Fc to other lipids tested
(Figures S5E and S5F). Intriguingly, high-density lipoprotein
(HDL) and low-density lipoprotein (LDL), which were thought to
contain the candidate lipid ligands, also bound to an extracellular
domain of LMIR3 and induced GFP expression in 2B4-LMIR3-
GFP cells, but not in 2B4-GFP cells (Figures 5D and S5E). Alter-
natively, several types of liposomes were generated. The binding
and functional assays with liposome-coated plates confirmed
that C-24 ceramide and PC, but not PS, bound to an extracellular
domain of LMIR3 and induced GFP expression in 2B4-LMIR3-
GFP cells (Figure S5G and data not shown). Notably, the addition
of liposomal suspensions of C-24 ceramide and PC, but not of
PS, to the culture induced GFP expression in the reporter cells
(Figure S5H). Taken together, our results demonstrated that
several lipids, including ceramide, and lipoproteins are endoge-
nous ligands for LMIR3.
Upon FcεRI Engagement, the Extracellular Ceramide-
LMIR3 Interaction Inhibited Activation of BMMCs
To clarify the role of the candidate ligands for LMIR3 in mast
cells, IgE-sensitized WT or Cd300lf/ BMMCs were stimulated
with specific antigens on plates coated with the indicated lipids
and lipoproteins. Incubation of BMMCs on the coated plates formmunity 37, 827–839, November 16, 2012 ª2012 Elsevier Inc. 831
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Figure 4. Mast Cell-Dependent Airway Inflammation and Dermatitis Were Exacerbated in LMIR3-Deficient Mice
(A–C) Analysis of WT or Cd300lf/ mice at 48 hr after the last challenge with OVA or PBS in airway inflammation model.
(A) Sections of lung tissues were stained with hematoxylin and eosin. Scale bars represent 500 mm.
(B) Numbers of total cells (Total), eosionophils (Eos), neutrophils (Neu), lymphocytes (lym), or macrophages (Mf) included in BALF (n = 6 per genotype).
(C) Amounts of IL-4, IL-5, or IL-13 in BALF. OVA, n = 6 per group; PBS, n = 3 per group.
(D–F) AD-like skin lesions were induced by repeated application of dust mite extract.
(D) Ear thickness was measured in WT, Cd300lf/, and KitW-sh/W-sh mice (n = 5 per genotype) during 19 days after the first treatment.
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Ceramide Is a Ligand for LMIR3 in Mast Cells24 hr did not affect mast cell viability (data not shown). Remark-
ably, inhibited b-hesosaminidase release was noted in WT
BMMCs on the plates coated with ceramide, SPC, HDL, or
LDL (Figure 6A). However, this inhibition was not observed in
Cd300lf/ BMMCs (Figure 6A). We found no inhibition of
b-hesosaminidase release in BMMCs on either the PC- or PS-
coated plates (Figure 6A). Similarly, FcεRI-mediated cytokine
production was inhibited in WT, but not Cd300lf/, BMMCs
on the plates coated with ceramide, SPC, HDL, or LDL (Fig-
ure 6B). These results indicated that ceramide, SPC, and lipo-
proteins worked as physiological ligands for LMIR3 in mast cells.
Furthermore, similar experiments were conducted in Cd300lf/
BMMC transfectants. Marked inhibition of both degranulation
and cytokine production was found in LMIR3 WT-transduced
Cd300lf/ BMMCs, but in neither LMIR3(Y241F-Y289F-Y325F)
mutant- normock-transducedCd300lf/BMMCs, on the plates
coated with ceramide, SPC, and lipoproteins (Figures 6C
and 6D). We did not find any effect of PS or PC on degranulation
or cytokine production of BMMC transfectants (Figures 6C and
6D). In addition, the inhibitory effect of plate-coated ceramide
on FcεRI-mediated degranulation ofWTBMMCswas dampened
by the addition of a soluble LMIR3 Ab before antigen stimula-
tion (Figure S6). Thus, a soluble LMIR3 Ab worked as a blocking
Ab to interfere with the extracellular ceramide-LMIR3 interaction.
We next examined the tyrosine phosphorylation levels of LMIR3
inWTBMMCson ceramide- or vehicle-coated plates. The results
showed that FcεRI crosslinking induced the tyrosine phos-
phorylation of LMIR3 and subsequent recruitment of SHP-1
and SHP-2, but not of SHIP, to tyrosine-phosphorylated LMIR3
in BMMCs only on the ceramide-coated plates (Figure 6E). In
accordance, the ceramide-LMIR3 interaction reduced the
levels of ERK phosphorylation in BMMCs stimulated by FcεRI
crosslinking (Figure 6E). It should be noted that LMIR3 was not
tyrosine phosphorylated in BMMCs on the ceramide-coated
plates without FcεRI engagement (Figure 6E).
Extracellular Ceramide-LMIR3 Interaction Inhibited
FcεRI-Mediated Activation of Mast Cells In Vivo
For further analysis, we used liposomal ceramides that could be
administered to mice. Consistently, FcεRI-mediated degranula-
tion of WT BMMCs, but not ofCd300lf/BMMCs, was inhibited
by the addition of liposomal ceramides to the culture before
antigen stimulation. On the other hand, it was not affected by
the addition of liposomal PC or liposomal PS to the culture (Fig-
ure 7A). We then explored the localization of FcεRI and LMIR3 in
IgE-sensitized BMMCs in the presence of specific antigen and
liposomal ceramides. Confocal microscopic analyses were
performed with Abs against LMIR3 and IgE. In the absence of
antigen and liposomal ceramides, both IgE-bound FcεRI and
LMIR3 were mainly expressed in the surface of BMMCs, but
were not frequently colocalized (Figure 7B). The addition of
liposomal ceramides alone did not significantly influence the
localization patterns (Figure 7B). On the other hand, antigen
stimulation alone induced some degree of colocalization of(E) Hematoxylin and eosin-stained ear sections in WT or Cd300lf/ mice at 19 d
(F) Ear thickness was measured in KitW-sh/W-sh mice engrafted with Cd300lf/
mock (n = 5 per group) during 16 days after the first application.
Data are representative of three independent experiments (mean and SD in B–D
IIgE-bound FcεRI and LMIR3 in the surface and cytoplasm of
BMMCs at 10 min after stimulation (Figure 7B). Remarkably,
the addition of both liposomal ceramides and antigen led to
the stronger and more frequent colocalization of FcεRI and
LMIR3 than that of antigen alone at the same time point (Fig-
ure 7B). These results were compatible with the notion that FcεRI
engagement was required for the substantial tyrosine phosphor-
ylation of LMIR3 through the ceramide-LMIR3 interaction. To
test the effect of liposomal ceramides on PCA responses, WT
or Cd300lf/ mice were pretreated with liposomal ceramides,
PC, or PS in the ears 24 hr before antigen stimulation. Intrigu-
ingly, only when pretreated with liposomal ceramides, WT
mice, but not Cd300lf/ mice, exhibited the diminished PCA
responses (Figure 7C), supporting the hypothesis that extracel-
lular ceramides worked as ligands for LMIR3 in tissue mast cells.
We next investigated the distribution of ceramides in vivo, by
using ceramide Ab that specifically bound to ceramide (Fig-
ure S7A). We confirmed that the addition of a soluble ceramide
Ab blocked GFP expression induced by plate-coated ceramide,
but not by either SPC or PC, in 2B4-LMIR3-GFP cells (Fig-
ure S7B). In addition, HDL- or LDL-induced inhibition of degran-
ulation and cytokine production of BMMCs stimulated by FcεRI
engagement was substantially impaired by the addition of a
soluble ceramide Ab (Figure S7C). Confocal microscopic anal-
yses on frozen tissue sections showed that ceramides were
distributed not only within cells but also outside DAPI-positive
cells in tissues examined (Figure S7D). Expression levels of
extracellular ceramides tended to be higher in stomach, skin,
or brain (Figure S7D). As previously reported, extracellular
ceramides were abundant in epidermis of ear skins, whereas
diffuse or patchy expression of extracellular ceramides were
also found in dermis, where tryptase-positive mast cells
were located (Figure 7D). Extracellular ceramides in tissues
were round, linear, or dot-like shaped (Figure 7D). It should be
noted that chronic skin and airway inflammation tended to
elevate expression of extracellular ceramides (Figure S7E).
Importantly, we found frequent contact of extracellular ceram-
ides with mast cells in ear skin (Figure 7D). Furthermore,
intradermal injection with ceramide Ab in the ears of WT mice,
but not Cd300lf/ mice, led to exacerbated PCA responses
(Figure 7E). Collectively, the interaction between extracellular
ceramides and LMIR3 negatively regulated FcεRI-mediated acti-
vation of mast cells in vivo.
DISCUSSION
The severity of mast cell-dependent allergic responses depends
on the types and amounts of chemical mediators secreted by
activated mast cells as the net result of positive and negative
signaling events (Kawakami and Galli, 2002; Kraft and Kinet,
2007; Kalesnikoff and Galli, 2008). Negative regulators of mast
cell activation prevent spontaneous and excessive activation of
mast cells that would be harmful to the host. Mice deficient in
an inhibitory receptor, such as PIR-B, gp49B1, FcRgIIb, orays from the first application. Scale bars represent 100 mm.
BMMCs transduced with LMIR3 WT, LMIR3(Y241F-Y289F-Y325F) mutant, or
, F). *p < 0.01 (Student’s t test). See also Figure S4.
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Figure 5. Identification of Possible Ligands for LMIR3
(A) LMIR3-Fc, TIM1-Fc, or Fc were incubated with strips spotted with the indicated lipids and immunoblotted with Ab against human IgG. Data are representative
of four independent experiments.
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Figure 6. Extracellular Ceramide-LMIR3
Interaction Inhibited FcεRI-Mediated Acti-
vation of BMMCs
(A–D) Anti-TNP IgE-sensitized BMMCs were
stimulated with 100 ng/ml TNP-BSA for 1 hr (A and
C) or 10 ng/ml TNP-BSA for 8 hr (B and D) on plates
coated with indicated lipids, lipoproteins, or
vehicle. Release of b-hexosaminidase (A and C) or
production of IL-6 (B and D) in WT or Cd300lf/
BMMCs (A and B) or Cd300lf/ BMMCs trans-
duced with LMIR3 WT, LMIR3(Y241F-Y289F-
Y325F) mutant, or mock (C and D) on each plate.
Data are representative of three independent
experiments (mean and SD); *p < 0.01 (Student’s
t test).
(E) Anti-TNP IgE-sensitized WT BMMCs were
stimulated with or without 100 ng/ml TNP-BSA for
indicated periods on plates coated with either
C-24 ceramide or vehicle. Immunoprecipitates of
cell lysates with LMIR3 Ab (AF2788) or total cell
lysates were immunoblotted with indicated Abs.
Data are representative of three independent
experiments. See also Figure S6.
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Ceramide Is a Ligand for LMIR3 in Mast CellsAllergin I, exhibit enhanced FcεRI-mediated anaphylaxis,
whereas coengagement of FcεRI and such an inhibitory receptor
is needed to suppress FcεRI-mediated activation of mast cells
in vitro, except in the case of FcgRIIb and PIR-B (Dae¨ron et al.,
1995; Ono et al., 1996; Kubagawa et al., 1997; Ujike et al.,
1999; Daheshia et al., 2001; Masuda et al., 2007; Hitomi
et al., 2010). IgE can bind to FcgRIIb, so immune complexes
composed of IgE and specific antigens coengage FcgRIIb and
FcεRI in BMMCs, thereby suppressing FcεRI-mediated activa-
tion of mast cells (Ujike et al., 1999). Because both PIR-B and
its ligand, major histocompatibility complex (MHC) class I, are
highly expressed in BMMCs, constitutive cis binding between(B–D) 2B4-GFP cells or 2B4-LMIR3-GFP cells were incubated for 24 hr on plates coated with the indicated
(3-14-11) or isotype control Ab was added to the culture just after the incubation of the reporter cells on the
(B and D) Flow cytometry of GFP expression of the reporter cells.
(C) IL-2 production of 2B4-LMIR3-GFP cells or 2B4-GFP cells incubated for 24 hr on plates coated with C-2
Data are representative of three independent experiments (mean and SD). See also Figure S5.
Immunity 37, 827–839, NPIR-B and MHC class I inhibits FcεRI-
mediated activation of BMMCs (Masuda
et al., 2007). Thus, whether an inhibitory
receptor downregulates mast cell activa-
tion in vitro or in vivo depends on the
expression profiles of its ligand.
In the present study, we demonstrate
that LMIR3 is a critical negative reg-
ulator of mast cell activation in vivo. In
fact, LMIR3 deficiency considerably aug-
mented mast cell-dependent allergic
responses in mice, such as passive
anaphylactic reactions, chronic airway
inflammation, and AD-like dermatitis.
Analysis of mast cell-deficient mice en-
grafted with BMMCs delineated that
LMIR3 deficiency in mast cells was
responsible for the enhanced allergicresponses in Cd300lf/ mice. In addition, it was clear that
LMIR3 inhibited mast cell activation in vivo through its two ITIMs
and/or a single ITSM.
Importantly, we identify a ligand for LMIR3. Although lipids
have been recently suggested as LMIR ligands (Choi et al.,
2011; Cannon et al., 2012), we assume that a functional LMIR3
ligand must fulfill at least two conditions. First, it must be signif-
icantly bound by LMIR3-Fc in comparison to control Fc. Second
and most critically, its binding to an extracellular domain of
LMIR3 must be able to aggregate a chimera receptor LMIR3-
CD3z, resulting in an ITAM-dependent GFP expression in the
2B4-LMIR3-GFP cells. The observation that LMIR3 deficiencylipids or lipoproteins. 20 mg/ml of either LMIR3 Ab
coated plates.
4 ceramide, LMIR3 Ab (3-14-11), or vehicle.
ovember 16, 2012 ª2012 Elsevier Inc. 835
A
B
C
D
E
Figure 7. Extracellular Ceramide-LMIR3
Interaction Inhibited FcεRI-Mediated Acti-
vation of Mast Cells In Vivo
(A) Anti-TNP IgE-sensitized WT or Cd300lf/
BMMCs were incubated with 100 ng/ml TNP-BSA
and 20 mg/ml of indicated liposomes for 1 hr to
measure the release of b-hexosaminidase. Data
are representative of three independent experi-
ments (mean and SD); *p < 0.01 (Student’s t test).
(B) Confocal imaging of IgE-bound FcεRI (green)
and LMIR3 (red) in BMMCs. Anti-TNP IgE-
sensitized BMMCs were incubated with 100 ng/ml
TNP-BSA and/or 20 mg/ml of liposomal C-24
ceramides for 10 min. After fixation, BMMCs were
stained with IgE Ab and LMIR3 Ab (AF2788). Scale
bar represents 10 mm.
(C and E) Mice were injected intravenously with
Evans blue dye containing DNP-HSA after IgE
sensitization. Quantification of Evans blue dye that
had extravasated into ears. Data are representa-
tive of three independent experiments (mean and
SD). *p < 0.05 (Student’s t test).
(C) WT or Cd300lf/ mice injected intradermally
with 20 mg of liposomes composed of C-24
ceramides, PC, or PS together with anti-DNP IgE
(n = 6 per group).
(D) Confocal imaging of frozen sections of ear skin
that were stained with ceramide Ab (ceramides;
green) and Mast Cell Tryptase Ab (mast cells; red).
Scale bars represent 50 mm (upper left) and 10 mm
(bottom left, upper right, and bottom right).
(B and D) The nuclei were counterstained with
DAPI (blue). Data are representative of five inde-
pendent experiments.
(E) WT or Cd300lf/ mice injected intradermally
with 20 mg of either ceramide Ab (MID 15B4) or
isotype control Ab together with anti-DNP IgE (n =
5 per group).
See also Figure S7.
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Ceramide Is a Ligand for LMIR3 in Mast Cellsenhanced in vivo mast cell degranulation, an event occurring at
the initial phase of anaphylactic responses, led us to speculate
that LMIR3 ligands were expressed in the surroundings of tissue
mast cells. Extensive ligand screening did not show that cell
surface proteins or extracellular matrix proteins are possible
ligands for LMIR3. Instead, several extracellular lipids and
lipoproteins, including ceramide, SPC, LDL, and HDL, satisfied
the necessary conditions for LMIR3 ligands. Interestingly, the
binding of these lipids and lipoproteins to LMIR3 inhibited
FcεRI-mediated activation of BMMCs, implicating these lipids
and lipoproteins as functional ligands for LMIR3 in mast cells.
On the other hand, PC appeared not to be a ligand for LMIR3
in mast cells, notwithstanding that PC worked as a ligand
for LMIR3-CD3z in the reporter cells. Although the reason is
unknown, it might be in part due to the subtle structural differ-
ence of an extracellular domain between endogenous LMIR3
and a chimera receptor LMIR3-CD3z. Alternatively, surface
components of mast cells might interfere with the recognition
of PC by LMIR3. In addition, our results did not provide any836 Immunity 37, 827–839, November 16, 2012 ª2012 Elsevier Inc.evidence that PS, including liposomal
PS, is a ligand for LMIR3 (Choi et al.,
2011), although we cannot exclude thepossibility that LMIR3 is involved in the recognition of dead cells
via its interaction with certain lipids. It should be noted that our
experimental procedures were not the same as those of Choi
et al. (2011). Interestingly, LMIR3 ligands ceramide and SPC
are generated from SM via the activity of sphingomyelinase
and sphingomyelindeacylase, respectively (Kolesnick, 2002;
Meyer zu Heringdorf et al., 2002; Zheng et al., 2006), implying
that LMIR3 recognizes the specific structure of the lipids. The
finding that lipoprotein-induced inhibition of FcεRI-mediated
mast cell activation was substantially impaired by the addition
of a soluble ceramide Ab indicated that among the components
of lipoproteins, ceramide was a major ligand for LMIR3 in mast
cells. In any case, the in vivo role of the candidate lipids for
LMIR3 should depend on the extracellular distribution in tissues.
Immunohistochemical analyses revealed that extracellular
ceramides were expressed in various tissues. The dot-like stain-
ing might reflect liposomal structures of ceramides, including
exosomes and lipoproteins, whereas round or linear ceramides
might be derived from dead cells and bound to structural
Immunity
Ceramide Is a Ligand for LMIR3 in Mast Cellsproteins of the extracellular matrix. Intriguingly, we found
frequent contact of extracellular ceramides with mast cells in
the dermis. Because mast cells are located in the surroundings
of blood vessels, it is possible that ceramide-containing lipopro-
teins that circulate in the blood and tissues work as LMIR3
ligands. Importantly, intradermal pretreatment with either
LMIR3 Ab, LMIR3-Fc, or ceramide Ab enhanced PCA responses
in WT mice but not Cd300lf/ mice. On the other hand, intra-
dermal pretreatment with liposomal ceramides diminished PCA
responses in WT mice but not in Cd300lf/ mice. Collectively,
these results indicated that the ceramide-LMIR3 interaction
was pivotal in LMIR3-mediated inhibition of mast cell activation
in vivo. Given that extracellular ceramide levels tended to be
elevated in chronically inflamed skin or lungs, it is possible that
the extracellular ceramide-LMIR3 interaction plays a prominent
role in the negative regulation of mast cell-dependent chronic
inflammation. In support of this, extremely severe inflammation
was observed in Cd300lf/ mice subjected to mast cell-
dependent chronic inflammation models. Therefore, it is also
interesting to speculate that the increase or decrease of extra-
cellular ceramides in tissues might influence susceptibility to
mast cell-dependent allergic diseases. Although the decrease
of ceramide levels in the skin is thought to be associated with
the barrier dysfunction that causes AD (Kawakami et al., 2009),
it may also accelerate mast cell-dependent inflammation in AD
as a result of the lack of ceramide-LMIR3 interaction in the
skin. A recent report that AD-like skin legions were inhibited by
topical application of a ceramide derivative appears to support
this possibility (Kang et al., 2007).
The molecular mechanism by which the extracellular
ceramide-LMIR3 interaction inhibited FcεRI-mediated activa-
tion of mast cells in vivo remains to be determined. Taking our
observations together, we assume the relevant mechanism to
be as follows. In tissues, mast cells are surrounded by extracel-
lular ceramides, either in liposomal forms or in protein-bound
forms. The interaction of extracellular ceramides with LMIR3
in mast cells fails to significantly deliver an inhibitory signal
without FcεRI engagement. When IgE-sensitized mast cells
are encountered with specific antigens, both extracellular ce-
ramide-LMIR3 interaction and FcεRI aggregation cooperatively
induce a strong colocalization of LMIR3 and FcεRI in mast cells,
where ITIMs and/or ITSM of LMIR3 are considerably tyrosine
phosphorylated presumably by activated Src family kinases
and/or Syk kinase recruited to b and g chains of FcεRI. As
a result, FcεRI-mediated activation of mast cells is likely to be
downregulated by the protein tyrosine phosphatases recruited
to LMIR3. Further examination is required to fully understand
the precise mechanism of LMIR3-mediated inhibition of FcεRI
signaling via colocalization of ceramide-bound LMIR3 and
FcεRI in mast cells.
We conclude that the interaction between extracellular ceram-
ide and LMIR3 negatively regulates FcεRI-mediated mast cell
activation and MC-related allergic diseases.EXPERIMENTAL PROCEDURES
Cells
2B4-GFP cell lines (Ohtsuka et al., 2004; Yamasaki et al., 2008) were kind gifts
from T. Saito (RIKEN Research Center for Allergy and Immunology). BMMCsIand transfectants were generated as described (Kitaura et al., 2003; Izawa
et al., 2009).
Binding Assay via Solid-Phase ELISA
Solid-phase ELISA was also used (Kobayashi et al., 2007). In brief, the indi-
cated lipids in methanol (10 mg/ml) or methanol as a control was added to
ELISA plates and air-dried. Alternatively, plates were coated with 10 mg/ml
of protein, PBS as a control, or 20 mg/ml of liposomes. After washing, the plates
were incubated with 10 mg/ml of LMIR3-Fc or Fc in the presence of 0.5 mM
CaCl2 for 120 min before incubating with peroxidase-conjugated anti-human
Ig (Sigma). Absorbance at 450 nm was measured.
Flow Cytometry
Flow cytometric analysis was performed with FACSCalibur (BD Biosciences)
equipped with CellQuest software and FlowJo software (Tree Star) (Yamanishi
et al., 2008).
Transfection and Infection
Retroviral transfection was done as described (Morita et al., 2000; Kitamura
et al., 2003). Retroviruses were generated by transient transfection of PLAT-E
packaging cells (Morita et al., 2000).
BMMC Reconstitution
KitW-sh/W-sh mice were injected intradermally with either 1 3 106 of WT or
Cd300lf/ BMMCs or 13 106 of BMMC transfectants 8 weeks before induc-
tion of PCA and AD-like model. Alternatively, KitW-sh/W-sh mice were injected
intravenously with either 23 106 of WT orCd300lf/BMMCs 5months before
induction of an airway inflammation model.
Quantification of Mast Cells
Mast cells were stained with toluidine blue and quantified as described
(Grimbaldeston et al., 2005).
Induction of PSA
Mice were injected intravenously with 1 mg DNP-HSA 24 hr after the in-
travenous injection of 5 mg mouse anti-DNP IgE (H1-ε-26). Rectal temperature
changes were monitored (Masuda et al., 2007). In some experiments, 50 mg
of CV6029 (Santa Cruz Biotechnology), 100 mg of cyproheptadine (Sigma),
or vehicle was intraperitoneally injected 1 hr before antigen challenge.
Induction of PCA
Mice were sensitized with the intradermal injection of 50 ng anti-DNP IgE
(H1-ε-26) or PBS to each ear. The mice were injected intravenously with 1%
Evans blue dye (Sigma) containing 250 mg DNP-HSA 24 hr after the sensitiza-
tion. The amounts of extravasated dye at 30 min after antigen challenge were
measured by absorbance at 450 nm (Hata et al., 1998). In some experiments,
CV6029, cyproheptadine, or vehicle was intraperitoneally injected 1 hr before
antigen challenge or 10 mg of LMIR3 Ab (3-14-11), ceramide Ab (MID 15B4),
isotype control Ab, LMIR3-Fc, Fc, or 20 mg of liposomes was injected intrader-
mally together with anti-DNP IgE (H1-ε-26) in ears. Alternatively, 10 ml of 0.3%
dinitrofluorobenzene (Wako) in acetone and olive oil (4:1) was painted on both
sides of ears 24 hr after the sensitization. Ear thickness was periodically
measured (Hata et al., 1998). After ears were fixed with 10% formaldehyde
and embedded in paraffin, sections were stained.
Airway Inflammation
Mice were intraperitoneally sensitized with 10 mg OVA (Sigma) at days 0, 7, 14,
21, 28, and 35. Then the mice were intranasally challenged with 20 mg OVA
or PBS at days 40, 43, and 46, and sacrificed 24 hr after the last challenge
(Williams and Galli, 2000; Taube et al., 2004; Xiao et al., 2011). All the proce-
dures were approved by an institutional review committee of the University
of Tokyo (approval no. 20-8).
Induction of AD-like Skin Lesions
Induction of AD-like skin lesions in mice was performed as described
(Kang et al., 2007). In brief, 200 mg of crude extracts of Dermatophagoides
pteronyssinus (DPE) (Biostir) was painted onto the dorsal surface of each ear
three times a week for 19 days. Ear thickness was periodically measured.mmunity 37, 827–839, November 16, 2012 ª2012 Elsevier Inc. 837
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Results are expressed as means ± SD. An unpaired Student’s t test was used
for all the statistical analyses.
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